| 1. |
Allweiss L, Dandri M. The role of cccDNA in HBV maintenance. Viruses, 2017, 9(6): 156.
|
| 2. |
Balmasova IP, Yushchuk ND, Mynbaev OA, et al. Immunopathogenesis of chronic hepatitis B. World J Gastroenterol, 2014, 20(39): 14156-14171.
|
| 3. |
Al-Busafi SA, Alwassief A. Global perspectives on the hepatitis B vaccination: challenges, achievements, and the road to elimination by 2030. Vaccines (Basel), 2024, 12(3): 288.
|
| 4. |
GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol, 2022, 7(9): 796-829.
|
| 5. |
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1204-1222.
|
| 6. |
Burki T. WHO's 2024 global hepatitis report. Lancet Infect Dis, 2024, 24(6): e362-e363.
|
| 7. |
Dai H, Alsalhe TA, Chalghaf N, et al. The global burden of disease attributable to high body mass index in 195 countries and territories, 1990-2017: an analysis of the Global Burden of Disease Study. PLoS Med, 2020, 17(7): e1003198.
|
| 8. |
Zhou XD, Chen QF, Yang W, et al. Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021. EClinicalMedicine, 2024, 76: 102848.
|
| 9. |
Wang Y, Zhao L, Gao L, et al. Health policy and public health implications of obesity in China. Lancet Diabetes Endocrinol, 2021, 9(7): 446-461.
|
| 10. |
Cho HJ, Park SG. Regulation of hepatitis B virus cccDNA by metabolic pathways. Clin Mol Hepatol, 2025.
|
| 11. |
Zhou L, He R, Fang P, et al. Hepatitis B virus rigs the cellular metabolome to avoid innate immune recognition. Nat Commun, 2021, 12(1): 98.
|
| 12. |
Li W, Deng R, Liu S, et al. Hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy: the emerging role of non-viral risk factors. Liver Int, 2020, 40(10): 2316-2325.
|
| 13. |
Yu MW, Shih WL, Lin CL, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol, 2008, 26(34): 5576-5582.
|
| 14. |
Kim M, Jun BG, Shin HS, et al. Impact of high body mass index on hepatocellular carcinoma risk in chronic liver disease: a population-based prospective cohort study. PLoS One, 2025, 20(1): e0316175.
|
| 15. |
Wang M, Yan L, Wang J, et al. Global burden of hepatitis B attributable to modifiable risk factors from 1990 to 2019: a growing contribution and its association with socioeconomic status. Global Health, 2023, 19(1): 23.
|
| 16. |
Cao G, Liu J, Liu M. Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study. Chin Med J (Engl), 2022, 135(17): 2049-2055.
|
| 17. |
Yan M, Wu B. Hepatitis B and C mortality from 1990 to 2019 in China: a Bayesian age-period-cohort analysis. Ann Transl Med, 2022, 10(24): 1384.
|
| 18. |
GBD 2019 Viewpoint Collaborators. Five insights from the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1135-1159.
|
| 19. |
GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1223-1249.
|
| 20. |
GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet, 2024, 403(10440): 2162-2203.
|
| 21. |
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 2016, 388(10053): 1545-1602.
|
| 22. |
GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 2017, 390(10100): 1345-1422.
|
| 23. |
Chevan A, Sutherland M. Revisiting Das Gupta: refinement and extension of standardization and decomposition. Demography, 2009, 46(3): 429-449.
|
| 24. |
GBD 2019 Under-5 Mortality Collaborators. Global, regional, and national progress towards Sustainable Development Goal 3. 2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019. Lancet, 2021, 398(10303): 870-905.
|
| 25. |
Wang P, Huang S, Wang R, et al. Global burden and cross-country inequalities in diseases associated with high body mass index from 1990 to 2019: result from the Global Burden of Disease Study 2019. J Glob Health, 2024, 14: 04200.
|
| 26. |
Hosseinpoor AR, Bergen N, Schlotheuber A. Promoting health equity: WHO health inequality monitoring at global and national levels. Glob Health Action, 2015, 8: 29034.
|
| 27. |
Lin Y, Jiang B, Cai Y, et al. The global burden of glaucoma: findings from the Global Burden of Disease 2019 Study and predictions by Bayesian age-period-cohort analysis. J Clin Med, 2023, 12(5): 1828.
|
| 28. |
Yan R, Sun M, Yang H, et al. 2024 latest report on hepatitis B virus epidemiology in China: current status, changing trajectory, and challenges. Hepatobiliary Surg Nutr, 2025, 14(1): 66-77.
|
| 29. |
Tan Y, Wei S, Zhang W, et al. Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review. Cancer Manag Res, 2019, 11: 705-713.
|
| 30. |
Zang Y, Xu W, Qiu Y, et al. Presence of diabetes further heightens hepatocellular carcinoma risk in patients with hepatitis B or hepatitis C virus-related cirrhosis: a meta-analysis. Heliyon, 2023, 9(8): e18425.
|
| 31. |
Kukla M, Mazur W, Bu?dak RJ, et al. Potential role of leptin, adiponectin and three novel adipokines-visfatin, chemerin and vaspin-in chronic hepatitis. Mol Med, 2011, 17(11-12): 1397-1410.
|
| 32. |
Udomsinprasert W, Honsawek S, Poovorawan Y. Adiponectin as a novel biomarker for liver fibrosis. World J Hepatol, 2018, 10(10): 708-718.
|
| 33. |
McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology, 2021, 73(Suppl 1): 4-13.
|
| 34. |
Liu F, Guo Z, Dong C. Influences of obesity on the immunogenicity of hepatitis B vaccine. Hum Vaccin Immunother, 2017, 13(5): 1014-1017.
|
| 35. |
Qiu J, Zhang S, Feng Y, et al. Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses. Expert Rev Vaccines, 2024, 23(1): 69-81.
|
| 36. |
Poobalan A, Aucott L. Obesity among young adults in developing countries: a systematic overview. Curr Obes Rep, 2016, 5(1): 2-13.
|
| 37. |
GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med, 2017, 377(1): 13-27.
|
| 38. |
Wrigley-Field E. Multidimensional mortality selection: why individual dimensions of frailty don't act like frailty. Demography, 2020, 57(2): 747-777.
|
| 39. |
Berry SD, Ngo L, Samelson EJ, et al. Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc, 2010, 58(4): 783-787.
|
| 40. |
Li X, Mukandavire C, Cucunubá ZM, et al. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet, 2021, 397(10272): 398-408.
|
| 41. |
Pelgrims I, Devleesschauwer B, Vandevijvere S, et al. The potential impact fraction of population weight reduction scenarios on non-communicable diseases in Belgium: application of the g-computation approach. BMC Med Res Methodol, 2024, 24(1): 87.
|
| 42. |
Wang AC, Geng JH, Wang CW, et al. Sex difference in the associations among risk factors with hepatitis B and C infections in a large Taiwanese population study. Front Public Health, 2022, 10: 1068078.
|
| 43. |
Nevola R, Tortorella G, Rosato V, et al. Gender differences in the pathogenesis and risk factors of hepatocellular carcinoma. Biology (Basel), 2023, 12(7): 984.
|
| 44. |
Chiu CM, Yeh SH, Chen PJ, et al. Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. Proc Natl Acad Sci U S A, 2007, 104(8): 2571-2578.
|
| 45. |
Wu MH, Ma WL, Hsu CL, et al. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med, 2010, 2(32): 32ra35.
|
| 46. |
Tong S. Hepatitis B virus, a sex hormone-responsive virus. Gastroenterology, 2012, 142(4): 696-699.
|
| 47. |
Patwardhan V, Gil GF, Arrieta A, et al. Differences across the lifespan between females and males in the top 20 causes of disease burden globally: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Public Health, 2024, 9(5): e282-e294.
|
| 48. |
Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther, 2020, 51(2): 216-230.
|
| 49. |
Sanai FM, Alghamdi H, Alswat KA, et al. Greater prevalence of comorbidities with increasing age: cross-sectional analysis of chronic hepatitis B patients in Saudi Arabia. Saudi J Gastroenterol, 2019, 25(3): 194-200.
|
| 50. |
Plass D, Hilderink H, Lehtom?ki H, et al. Estimating risk factor attributable burden - challenges and potential solutions when using the comparative risk assessment methodology. Arch Public Health, 2022, 80(1): 148.
|